Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Beth Israel Deaconess Medical Center
Boston, Estados UnidosPublications in collaboration with researchers from Beth Israel Deaconess Medical Center (4)
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for immunotherapy of cancer, Vol. 10, Núm. 5
2017
-
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936
2016
-
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma
Clinical Cancer Research
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine